Abstract
BackgroundSeveral biologic agents are currently approved to treat adult patients with rheumatoid arthritis (RA). To date, no analyses have compared the cost-efficacy of biologics using data from a head-to-head trial.ObjectivesTo...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
